Dupilumab治疗COPD的2型炎症生物标志物分析：BOREAS III期试验的预测价值与动态变化 《The Lancet Respiratory Medicine》：Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a ...

受试者每两周皮下注射Dupilumab 300mg或安慰剂，主要终点为年急性加重率，次要终点包括第一秒用力呼气容积（FEV 1）变化及圣乔治呼吸问卷（SGRQ）评分。 【研究结果】 急性加重控制：Dupilumab组年急性加重相对风险降低30-34%（p<0.001），绝对风险差达0.32-0.44次/年。

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Dupilumab is a "major advance for EoE that has to find its place but should be looked at with optimism and what I call tempered expectations," Philip Katz, MD, professor of medicine in the ...

Meeting Coverage > ACG Dupilumab Helped Kids With Eosinophilic Esophagitis Achieve Needed Weight Gain — The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil ...

The dupilumab group also saw an improvement in their hives symptoms, with an 8.5-point greater decrease versus the placebo group in their Urticaria Activity Score over 7 days (UAS7) for a mean ...

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody ...

Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.

• Dupilumab comes as a pre-filled syringe which has to be injected under the skin as a subcutaneous injection. • Before injecting dupilumab, it is necessary to allow the medication to come to ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...